Timber Pharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 21:1921:19, 20 August 2022 95.149.241.133 talk 1,336 bytes +11 No edit summary undo

14 August 2022

• curprev 08:3708:37, 14 August 2022 109.180.50.163 talk 1,325 bytes +15 No edit summary undo

31 July 2022

• curprev 11:3211:32, 31 July 2022 >Chris 1,310 bytes +1,310 Created page with "Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapam..."